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Objective: Our aim was to investigate in a real-life setting
whether stratification of patients with HDM allergy according
to molecular analysis may enhance AIT success.
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https://doi.org/10.1016/j.jaci.2020.03.029basophil activation. In vitro parameters were related to
reduction of symptoms determined by combined symptom
medication score and visual analog scale score.
Results: Alutard SQ 510 induced protective IgG mainly against
Dermatophagoides pteronyssinus (Der p) 1 and Der p 2 and to a
lesser extent to Der p 23, but not to the other important
allergens such as Der p 5, Der p 7, and Der p 21, showing better
clinical efficacy in patients sensitized only to Der p 1 and/or Der
p 2 as compared with patients having additional IgE
specificities.
Conclusion: Stratification of patients with HDM allergy
according to molecular sensitization profiles and molecular
monitoring of AIT-induced IgG responses may enhance the
success of AIT. (J Allergy Clin Immunol 2020;146:1097-108.)
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class, allergen microarray
Allergen-specific immunotherapy (AIT) is the only disease-
modifying treatment for patients with allergy that has long-lasting
effects.1,2 AIT seems to be even more effective than pharmaco-
therapy in reducing symptoms,3,4 and it prevents the progression
from mild forms of allergy (rhinoconjunctivitis) to severe forms
(asthma).5 However, several factors, such as long duration of
treatment with multiple applications and potential side effects,
lead to poor compliance of patients and thus limit utilization of
AIT.6,7 Another important problem relates to difficulties in ob-
taining high-quality allergen preparations for the formulation of
AIT vaccines.8 The latter problem is particularly relevant for
house dust mites (HDMs), which contain a variety of different
allergen molecules.9,10 HDMs are among the most important
allergen sources worldwide, and they are responsible for severe
forms of respiratory and cutaneous allergic manifestations.11
Because HDMs are rich in proteases and immunomodulatory
components,12 it is difficult to obtain high-quality allergen
extracts. In the HDM, Dermatophagoides pteronyssinus (Der p)
1, Der p 2, Der p 5, Der p 7, Der p 21, and Der p 23 seem to repre-
sent the most clinically relevant allergens13,14; however, most
allergen extracts prepared from natural allergen sources contain
mainly Der p 1 and Der p 2, whereas the other allergens occur
in small amounts or are missing. In this context, it has been
demonstrated that important allergens were missing from HDM
allergen extracts used for skin testing.15
Although several studies have demonstrated clinical efficacy of
subcutaneousAIT (SCIT) for the treatment of HDMallergy16-18 it1097
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seasonal allergies such as grass pollen allergy when vaccines of
the same type are compared (ie, when SCIT is compared with the
aluminium hydroxide–adsorbed allergen extract Alutard).19-22 In
fact, SCIT with the aluminium hydroxide–adsorbed HDM
allergen extract Alutard has been studied quite extensively in clin-
ical studies in adults and children.23,24 Analysis of the underlying
immunologic mechanisms indicated that the induction of
allergen-specific IgG4 antibodies not only served as a marker
for the immunologic response but was also partly associated
with clinical efficacy.23 Accordingly, the induction of allergen-
specific IgG, and the induction of allergen-specific IgG4 in partic-
ular, is currently considered an important biomarker for effects
and, in part, efficacy of AIT.25,26 Further support for the impor-
tance of allergen-specific IgG antibodies in reducing allergic
symptoms comes from a recent study demonstrating that passive
immunization with allergen-specific IgG mAbs potently sup-
pressed allergic symptoms in a clinical study.27 However, analysis
of the induction of allergen-specific IgG4 and the IgE-blocking
activity with crude HDM allergen extracts showed modest corre-
lations between clinical efficacy and IgE-blocking activity of the
therapy-induced IgG4 response.
23 Because HDMs (unlike cat,
birch pollen, or grass pollen) contain several different important
allergens that may not be well represented in natural allergen ex-
tracts, it is tempting to speculate that patients with different pro-
files of IgE reactivity to HDMallergensmay respond in a different
manner depending on presence of the individual HDM allergens
in the vaccine. In fact, the post hoc analysis of IgE and IgG re-
sponses of sera from patients undergoing a clinical trial with
HDM SCIT in which clinical effects were recorded in an allergen
challenge chamber indicated that the reduction of total nasal
symptom scores may be related to the patients’ IgE recognition
profiles and development of allergen-specific IgG.28
Here we have performed the first real-life study using a large
panel of purified HDM allergen molecules and analyzed the
molecular IgE sensitization profiles and development of allergen-
specific IgG antibodies in patients with HDM allergy who were
receiving SCIT with Alutard and in a parallel control group
without SCIT. In particular, we performed a detailed analysis
of allergen-specific IgG subclass responses. The ability of
treatment-induced IgG to inhibit allergen-induced basophil
degranulation was studied with multiple allergens, and immuno-
logic parameters were related to clinical outcome. The results of
our study indicate that molecular diagnosis and molecular
monitoring of AIT-induced IgG antibodies may be useful to
predict and monitor efficacy of HDM AIT in real life.METHODS
Subjects and treatment
We analyzed serum samples from 24 patients with HDM allergy who had
been treated with conventional HDM SCIT (Alutard-SQ 510, ALK-Abello,
The Netherlands) (a group of patients with HDM allergy who received
immunotherapy [referred to as the HDMIT group]), a group of 9 patients with
HDM allergy without immunotherapy (referred to as the HDMA group), and a
group of nonallergic subjects.29 Patients with HDM allergy had a positive skin
prick test (SPT) result with HDM, a level of Der p–specific IgE antibodies
greater than 0.35 kUA/L determined by ImmunoCAP (Phadia AB/Thermo-
Fisher, Uppsala, Sweden), and a clinical history of symptoms of allergy to
HDM. AIT was conducted for a 3-year period, and monitoring and sample
collection were performed for the first 12 months. One group of patients
with allergy (the HDMIT group) received weekly subcutaneous injections
for 15 weeks, with monthly injections for 1 year afterward. The dosage was
an escalation regimen from 100, 1,000, and 10,000 to 100,000 standardized
quality units per milliliter, which was reached at the end of the initiation
(15 weeks) and maintained for the remaining year (Fig 1). All patients were
treated at the Ghent University Hospital, in Ghent, Belgium; all data and sam-
ples were collected prospectively. At each visit—at baseline (at visit 0 [V0],
halfway through initiation (7 weeks [V1]), at the end of initiation (15 weeks
[V2]), after 8 months of maintenance (V3), and after 1 year of treatment
(V4) (Fig 1)—patients filled out questionnaires, underwent SPTs, had their
clinical symptoms assessed (with use of visual analog scale [VAS] scores
and combined symptommedication scores [CSMSs]), and had blood and nasal
secretions collected as described.30 During the same period, serum samples
and nasal secretions were obtained from the parallel HDMA group (n 5 9)
and from the group of nonallergic subjects (n 5 9). The study was approved
by the local ethical committee of Ghent University Hospital (EC 2013/672).
Written informed consent was obtained from each patient, including
permission to investigate their blood samples. Patients’ baseline
characteristics and immunologic parameters are displayed in Table I. The ano-
nymized serum samples were analyzed with permission from the ethics com-
mittee of the Medical University of Vienna (EK 1641/2014).
ImmunoCAP ISAC assay
Serum samples from the HDMIT group (n5 24), the HDMA group (n5 9),
and thegroupof nonallergic subjects (n59) that hadbeencollected at everyvisit
(V0-V4) were analyzed for IgE and IgG reactivity to multiple microarrayed
allergen molecules, including 15 HDM allergens (ie, Der p 1, Dermatopha-
goides farinae 1 [Der f 1], Der p 2, Der f 2, Der p 4, Der p 5, Der p 7, Der p
10, Der p 11, Der p 14, Der p 15, Der p 18, Der p 21, Der p 23, and Der p 37).
The samples were analyzed by using the MeDALL chip, which is based on
Immuno-solid-phase Allergen Chip (ISAC) microarray technology (Phadia
Multiplexing; ThermoFisher Scientific) as described.31 For IgE measurement,
serum samples were used undiluted, whereas for IgG measurement, sera were
diluted1:50.Resultswere evaluatedbyusingPhadiaMicroarray ImageAnalysis
software, and levels of allergen-specific IgE and IgG antibodies were reported in
ISAC standardized quality units for IgE antibodies or ISAC standardized quality
units for IgG antibodies, with a cutoff of 0.3 ISAC standardized quality units.HDM allergens and peptides
Natural purified Der p 1 was obtained from Professor W. R. Thomas.32 Re-
combinant Der p (rDer p) 2, rDer p 23, rDer p 5, and rDer p 21 were expressed
in Escherichia coli and purified as described.33-35 The expression and purifi-
cation of rDer p 7 are described in the Online Repository.
Peptides of Der p 1, Der p 2, and Der p 23 with a length between 29 and 43
amino acids, covering the sequences of the allergens (see Table E1 in this ar-
ticle’s Online Repository at www.jacionline.org), were synthesized by using a
9-fluorenylmethoxycarbonyl strategy as described elsewhere.36 The peptides
were identified by mass spectrometry and purified by preparative HPLC to a
purity greater than 90%.37 The sequences and numbers of amino acids of
each of the peptides, their location in the corresponding allergen, and the abil-
ity of peptide-specific IgG antibodies to inhibit IgE binding in patients with














FIG 1. Scheme of AIT treatment and sample collection. Patients received subcutaneous AIT consisting of a
15-week updosing period with 15 weekly injections (initiation) and monthly maintenance injections for 1
year (maintenance). Blood and nasal secretions were collected at visits 0 to 4, as indicated. SQ-U, Standard-
ized quality units.
TABLE I. Demographic and clinical characteristics of subjects included in the study
Group HDMIT group HDMA group Patients without allergy
No. 24 9 9
Median age, y 31.44 27.73 26.87
Sex (male/female) 9/15 4/5 3/6
Median length (cm) 170 170 168
Median weight (kg) 63.5 73 64
Median BMI (kg/m2) 21.65 22.84 23.71
Asthma (%) 46.67 11.11 na
Rhinitis (%) 100 100 na
Median total IgE, kU/L (range) 134.74 (16.45-1975.84) 80.06 (27.67-374.30) 13.81 (3.15-107.89)
Median D pteronyssinus sIgE level, kUA/L (range) 0.05-200.91 (19.43) 0.39-69.37 (4.87) na
Median D farinae sIgE level, kUA/L (range) 0.05-188.20 (12.78) 0.21-49.61 (5.35) na
Monosensitized to HDM, n (%) 6 (25.00) 4 (44.44) na
Cosensitizations, n (%) 18 (75.00) 5 (55.55) na
Grass, n (%) 16 (66.66) 4 (44.44) na
Tree, n (%) 9 (37.50) 1 (11.11) na
Weed, n (%) 3 (12.50) na na
Mold, n (%) 4 (16.66) 1 (11.11) na
Cat/dog, n (%) 15 (62.50) 2 (33.33) na
HDMA, Patients with HDM allergy who did not receive immunotherapy; HDMIT, patients with HDM allergy who received immunotherapy; na, not applicable.
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Allergen- and peptide-specific human IgG1, IgG2, IgG3, and IgG4 subclass
responses were measured by ELISA.38,39 For this purpose, serum samples
were diluted 1:50 and nasal secretions were diluted 1:4 in PBS containing
0.5% Tween 20. OD values were recorded on a FLUOstar Omega Microplate
Reader (BMG Labtech, Ortenberg, Germany). All determinations were per-
formed in duplicate, and the results were displayed as means of the OD values
with deviations less than 5%. OD values from different plates were harmo-
nized by including standards on each plate.
Quantitative IgG1 and IgG4 ELISA measurements were performed by
using 96-well ELISA plates (Nunc Maxisorp, Roskilde, Denmark). Each
well was coated with 100 mL of natural Der p 1, rDer p 2, or rDer p 23
(2 mg/mL in 100 mM carbonate buffer [pH 9.6]), after which the plates
were incubated for 5 hours at room temperature. After being washed
with 0.05% vol/vol Tween-20 (Sigma-Aldrich, St Louis, Mo) in PBS and
being blocked with 2% wt/vol BSA in PBS/0.05% Tween 20 overnight,
the plates were incubated with patients’ sera (diluted 1:50 and 1:100 in
PBS/0.05% Tween-20/0.5% BSA) for 2 hours at 378C and 1 hour at roomtemperature. Standard curves for IgG1 and IgG4 were established by
coating plates with 2 mg/mL of Phleum pratense (Phl p) 2 and Phl p 5
and incubating them with a human IgG1 mAb specific for Phl p 2
40 or
with a human IgG4 mAb specific for Phl p 5
41 with mAb concentrations
of 50, 150, 450, 900, and 1350 ng/mL diluted in PBS/0.05% Tween-20/
2% BSA in triplicate for 2 hours at 378C and 1 hour at room temperature.
Bound antibodies were detected with biotinylated subclass-specific anti-
bodies (mouse anti-human IgG1 mAb (clone G17-1) or IgG4 (clone G17-
4) (BD, San Diego, Calif) (diluted 1:1000 in PBS/0.05% Tween-20/0.5%
BSA) mixed with horseradish peroxidase–conjugated streptavidin (BD
Pharmingen, catalog no. 554066) (diluted 1:2500 in PBS/0.05% Tween-
20/0.5% BSA) overnight at 48C. The substrate 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) (Sigma-
Aldrich) was added at a rate of 100 mL per well, and the ODs were
measured by using an ELISA Reader (Tecan Infinite F50, M€annedorf,
Switzerland) at 405/490 nm. Concentrations of allergen-specific IgG1
and IgG4 were calculated according to the standard curve of OD values ob-
tained for known concentrations.
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activation with blocking IgG
Rat basophilic leukemia RBL cells (clone RS-ATL8)42 transfected with the
cDNA coding for the human high-affinity IgE receptor were maintained in
minimum essential medium (MEM) with Earle salt supplemented with 10%
FBS, 2mM L-glutamine (ThermoFisher Scientific), 100 U/mL of penicillin,
and 100mg/mL of streptomycin, 200mg/mL of Geneticin (ThermoFisher Sci-
entific), and 200 mg/mL of Hygromycin B (ThermoFisher Scientific) at 378C.
Cells were plated in 96-well sterile tissue culture plates (50 mL per well) with
the sera (1:20 dilution in supplemented MEM) obtained from the treated pa-
tients (n5 9) before immunotherapy at baseline (ie, at visit V0) and incubated
overnight at 378C and 7% CO2. For control purposes, cells were incubated
only with supplementedMEM as a negative control. The next day, serum sam-
ples that had been obtained from the same patients before and after AITwere
incubated for 1.5 hours at 568C to inactivate IgE antibodies. Thereafter, IgE-
inactivated sera diluted 1:20 in Tyrode buffer (ie, Tyrode salts dissolved in wa-
ter according to the manufacturer (Sigma Aldrich), 0.02M NaHCO3, 1% wt/
vol BSA, and 50% vol/vol D2O [ 7.2]) were incubated with different concen-
trations of purified allergens (1, 10, and 100 ng/mL) for 2 hours at 378C and
added to the cells, which had been washed 3 times with washing buffer (Ty-
rode salts, 0.02M NaHCO3, and 1% wt/vol BSA in H2O [pH 7.2]) for 1
hour at 378C. The release of b-hexosaminidase in the medium from activated
RBL cells was determined by a fluorometric assay by using 4-
methylumbelliferyl-N-acetyl-b-D-glucosaminide as a substrate (0.1 mM in
100 mM citrate [pH 4.5]). The reaction was stopped with 0.25 M glycine
buffer after 60 minutes of incubation at room temperature. The plate was
read on an Infinite M200 PRO series plate reader (TECAN Austria GmbH,
Gr€odig, Austria) by using 380-nm excitation and 440-nm emission filters.
All measurements were performed in triplicate, and the results were displayed
as percentages of total release (means 6 SDs).43
For measuring direct mediator release, cells were loaded with serum
obtained from patients before immunotherapy at baseline (V0) or afterward
(V4) and exposed to different concentrations of purified allergens (0.01 to 10
ng/mL). b-Hexosaminidase release was determined as described in the
preceding paragraph.43Statistics
The Mann-Whitney and Wilcoxon U tests were used to compare indepen-
dent samples fromdifferent subjects to compare the IgE and IgG levels, as well
as the IgG subclasses and allergen peptide ODs in different groups at the given
different time points (GraphPad Prism software, version 7.00 for Windows,
GraphPad Software, La Jolla, Calif). A P value less than .05 was considered
statistically significant, as indicated in the figure legends.RESULTS
Real-life study design and characterization of
patients with HDM allergy
To study immune responses in patients with HDM allergy who
were undergoing subcutaneous immunotherapy with HDM
allergen extract–based Alutard SQ 510, an investigator-driven
study was conducted at the Department of Otorhinolaryngology
in Ghent University Hospital in Ghent, Belgium.29 In this obser-
vational study patients with HDM allergy received subcutaneous
immunotherapy with HDM allergen extract–based Alutard SQ
510 for 3 years (those in the HDMIT group); a control group
without AIT (ie, those in the HDMA group) was also included.
Serum samples from 24 of the 28 patients in the HDMIT group
and all 9 patients in the HDMA group that had been obtained at
baseline (ie, visit 0), after week 7 (ie, visit 1), after week 15 (ie,
visit 2), after week 33 (ie, visit 3), and after week 52 (ie, visit
4) (Fig 1) were available for analysis. Table I provides an over-
view of the demographic and clinical characterization of theHDMIT group andHDMAgroup. Pseudonymized serum samples
and nasal secretion samples were analyzed by an investigator who
was blinded regarding the 2 groups.
Table II shows the molecular IgE recognition profiles of the pa-
tients in the HDMIT group and the patients in the HDMA group
when tested with 13 microarrayed D pteronyssinus allergen mol-
ecules, as well as with Der f 1 and Der f 2 at the baseline visit. In
the HDMIT group, Der p 2 (91.7%), Der p 1 (58.3%), and Der p
23 (45.8%) were the most frequently recognized allergen mole-
cules, followed by Der p 7 (41.7%), Der p 4 (33.3%), Der p 21
(29.2%), Der p 10 (20.9%), Der p 5 and Der p 37 (both 12.5%),
Der p 18 (8.3%), and Der p 15 (4.2%). In the HDMA group,
frequencies of recognition of IgE to the individual allergen
molecules were lower, which was in agreement with the lower
levels of Der p– and Der f–specific IgE (Table I). Fewer members
of the HDMA group had asthma than in the HDMIT group (ie,
11.1% vs 46.7%). A detailed demographic, clinical, and serologic
characterization of each of those in the HDMIT group and those in
the HDMA group can be found in Tables E2 and E3 (in this arti-
cle’s Online Repository at www.jacionline.org). Patients who
were sensitized only to Der p 1 and/or Der p 2 are indicated in
blue and those who are sensitized against at least 1 of the
additional clinically relevant allergens (ie, Der p 5, Der p 7,
Der p 21, and Der p 23) are highlighted in yellow in Tables E2
and E3.Vaccination with Alutard SQ 510 induces specific
IgG responses only to Der p 1, Der p 2, and Der p 23
and not to any of the other Der p allergen molecules
Fig 2 shows the development of allergen-specific IgG levels in
the HDMIT group compared with the levels in the HDMA group
during the observation period of 1 year. The patients in the
HDMIT group showed a significant increase in Der p 1–, Der f
1–, Der p 2–, and Der f 2–specific IgG responses in serum samples
obtained at visits 2, 3, and 4 compared with baseline. A much
lower but significant increase in Der p 23–specific IgG levels
was noted as well for the HDMIT group (Fig 2, B). However,
no relevant induction of IgG antibodies specific for any of the
other HDM allergens (Der p 5, Der p 7, or Der p 21 [Fig 2, A
and B] and Der p 4, Der p 10, Der p 11, Der p 14, Der p 15,
Der p 18, or Der p 37 [see Fig E1, A and B in this article’s Online
Repository at www.jacionline.org and see also Table E3]) was
found. No relevant HDM allergen–specific IgG increases were
found in the untreated HDMA group (Fig 2, A and B [see
Table E3]).
The analysis of allergen-specific IgE responses in the course
of AIT showed that the patients in the HDMIT group also had
increased levels of IgE to Der p 2, Der f 2, Der p 1, Der f 1,
and Der p 23 beginning with visit 2, with the levels going
down at visits 3 and 4 whereas levels of allergen-specific IgG
continued to increase (Fig 2, A and B). These increases in
allergen-specific IgE levels were observed only for those aller-
gens against which IgG was induced but not for the other
HDM allergen molecules. For certain patients in the HDMIT
group (ie, patients 008, 030, 032, 034, 037, 039, and 040),
we noted a de novo induction of allergen-specific IgE against
allergens that were not recognized at baseline (see Table E4
in this article’s Online Repository at www.jacionline.org).
When basophils were loaded with sera obtained from the latter
patients at baseline and after treatment we found that




Prevalence (%) Mean (SD) Prevalence (%) Mean (SD)
Der f 1 45.83 7.49 (12.15) 44.44 3.09 (4.45)
Der f 2 83.33 26.20 (37.43) 77.78 11.55 (23.64)
Der p 1 58.33 16.04 (27.63) 55.56 2.62 (4.79)
Der p 2 91.67 19.98 (31.83) 55.56 9.07 (18.07)
Der p 4 33.33 1.05 (0.68) 11.11 0.13 (0.22)
Der p 5 12.50 0.54 (0.16) 0.00 0.00 (0.00)
Der p 7 41.67 3.60 (3.96) 11.11 0.13 (0.34)
Der p 10 20.83 0.51 (0.17) 0.00 0.02 (0.03)
Der p 11 0.00 0.00 (0.00) 0.00 0.00 (0.00)
Der p 14 0.00 0.00 (0.00) 0.00 0.00 (0.01)
Der p 15 4.17 0.00 (0.00) 11.11 0.16 (0.47)
Der p 18 8.33 14.16 (19.37) 11.11 0.08 (0.23)
Der p 21 29.17 3.64 (5.52) 0.00 0.00 (0.00)
Der p 23 45.83 15.09 (34.66) 33.33 2.47 (7.07)
Der p 37 12.50 2.22 (2.58) 0.00 0.01 (0.03)
HDMA, Patients with HDM allergy who did not receive immunotherapy; HDMIT, patients with HCM allergy who received immunotherapy.
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mediator release in more than half of them (see Fig E2 in
this article’s Online Repository at www.jacionline.org). No in-
creases in allergen-specific IgE levels were found for the un-
treated HDMA group (Fig 2, A and B ).Maintenance treatment continuously increases
allergen-specific IgG4 responses but only maintains
IgG1 and IgG2 responses
Fig 3 presents the results obtained when allergen-specific IgG
subclass responses were analyzed in the HDMIT group during the
1-year period of investigation. The IgG subclass analysis was per-
formed only for those allergens against which increases in
allergen-specific IgG responses were found (ie, Der p 1, Der p
2, and Der p 23) and for control purposes, for 1 allergen for which
no IgG response was found (ie, Der p 5). Allergen-specific IgG
subclass responses were observed mainly for IgG1, IgG4, and
for IgG2 but not for IgG3, and they were limited to Der p 1, Der
p 2, and Der p 23, whereas no Der p 5–specific IgG subclass re-
sponses were found (Fig 3). We noted interesting differences
regarding the kinetics of the IgG subclass responses in the course
of treatment: allergen-specific IgG4 responses continued to in-
crease during the course of treatment, as shown for Der p 1,
Der p 2, and Der p 23. By contrast, allergen-specific IgG1 and
IgG2 responses were lower and did not further increase during
the maintenance treatment. Using a quantitative ELISA for
measuring the concentrations of allergen-specific IgG1 and
IgG4, we found that AIT-induced allergen-specific IgG1 concen-
trations were in the range of 5 mg/mL, whereas allergen-
specific IgG4 concentrations went up to approximately 25 mg/
mL (see Fig E3, A and B in this article’s Online Repository at
www.jacionline.org).
Allergen-specific IgG1 and IgG4 antibodies could be also de-
tected in nasal secretions, but their levels were low and increases
were noted only for specific IgG4 antibodies (see Fig E4 in this
article’s Online Repository at www.jacionline.org).
In the untreated (HDMA) group, allergen-specific IgG subclass
levels did not change during the year of investigation (data not
shown).IgG4 antibodies are only partly directed against the
IgE-binding regions of the allergens
IgG4 levels specific for 8 overlapping peptides of Der p 1, 5 Der
p 2 peptides, and 5 Der p 23 peptides, which covered the se-
quences of the allergens (see Table E1), were measured in sera
of patients from the HDMIT group that had been obtained before
immunotherapy (at V0), after 33 weeks (at V3), and after 1 year
(at V4) of immunotherapy. Table E1 indicates the percentages in
patients with allergy of inhibition of IgE binding to the corre-
sponding allergens obtained with peptide-specific antibodies
and thus define whether a peptide was derived from an IgE-
binding region.44,45 Statistically significant increases in IgG4
levels were found for all but 1 of the Der p 1 peptides (ie, peptide
1), which were associated with the most significant increases in
IgG4 against peptides 6, 7, and 8 (Fig 4). Thus, no induction of
IgG4 responses against peptide 1, which is part of the Der p 1
IgE-binding region, was found. Der p 2–specific IgG4 antibodies
induced during immunotherapy were directed against peptides 2
and 3 and most significantly against peptides 4 and 5 (Fig 4). No
development of IgG4 responses against peptide 1 from Der p 2,
which is part of the IgE epitope–containing region, was found.
Der p 23–specific IgG4 antibodies recognized mainly peptide 3,
which represents an IgE-reactive part of the allergen44 (Fig 4).
We therefore found that AIT-induced IgG4 was directed against
some but not all IgE-binding regions of the allergens and also re-
acted with areas not relevant for IgE binding.AIT-induced IgG antibodies inhibit mainly Der p 1–,
Der p 2–, and Der p 23–induced basophil activation
Next, we investigated whether AIT-induced IgG antibodies can
inhibit allergen-induced basophil activation (Fig 5 and see Fig E5
in this article’s Online Repository at www.jacionline.org). Exam-
ples are shown for 9 patients from the treatment group (HDMIT
group), which showed IgE reactivity not only to the major
HDM allergens, Der p 1, Der p 2, and Der p 23, but also to 1 or
more of the other HDM allergens (Fig 5 and see Fig E5). The
detailed analysis showed that an inhibition of basophil activation
by post-AIT sera was usually associated with the induction of
allergen-specific IgG antibodies (Fig 5 and see Fig E5).
FIG 2. IgG and IgE reactivity to HDM allergen molecules before and during AIT. IgE and IgG levels (y axes
show IgE in terms of standardized quality unit [ISU] and ISAC standardized quality unit for IgG antibodies
[ISU-G]) to Der p 1, Der p 2, Der f 1, and Der f 2 (A) and Der p 5, Der p 7, Der p 21, and Der p 23 (B), asmeasured
in sera of those patients in the HDMIT group (gray dots [n5 24]) and in the sera of those patients in the HDMA
group (black triangles [n5 9]), as determined by ISAC at different visits (x axes show values at V0 [baseline],
V1 [7 weeks], V2 [15 weeks], V3 [33 weeks], and V4 [1 year]). Red horizontal bars indicate median values.
Statistically significant differences are indicated as follows: *P < .05; **P < .01; ***P < .001; ****P < .0001.
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FIG 3. Development of allergen-specific IgG subclass responses in sera from patients in the HDMIT group
during AIT. IgG1, IgG2, IgG3, and IgG4 levels to Der p 1, Der p 2, Der p 5, and Der p 23 (y axes showOD values)
at different visits (x axes show values at V0 [baseline], V1 [7 weeks], V2 [15 weeks], V3 [33 weeks], and V4 [1
year]). Red horizontal bars indicate median values. Statistically significant differences are indicated as fol-
lows: *P < .05; **P < .01; ***P < .001; ****P < .0001.
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p 2–induced basophil activation (Fig 5, A and B and see Fig E5, A-
G). In the presence of AIT-induced IgG antibodies (V4) an
approximately 10-fold concentration of allergen was necessary
to induce basophil degranulation as compared with the concentra-
tion in serum obtained at baseline (at V0) (Fig 5 and see Fig E5,A-
G). An inhibition of Der p 23–induced basophil activation was
noted only for certain Der p 23–sensitized subjects (Fig 5, B
and see Fig E5, A, C, and E) but not for others (Fig 5, A and see
Fig E5, B, D, F, and G). Inhibition of basophil activation was
observed for Der p 7 in only 2 subjects (see Fig E5, A and B)
but not for the other allergens (ie, Der p 5 and Der p 21) and
not for other subjects. Der p 4 showed no or only very low aller-
genic activity when basophil activation was tested in sensitized
patients (patients 009, 019, 021, 027, 029, 033, 037, and 038
[see Table E2 and Fig E5, H]).Evidence that AIT with Alutard SQ 510 is clinically
less effective in patients with IgE reactivity to Der p
5, Der p 7, Der p 21, and/or Der p 23
CSMSs and VAS scores were assessed for each patient at
each visit (V0-V4), and then the percentages of reduction of
CSMSs and VAS scores between the baseline (V0) and the last
visit (at 1 year [V4]) were calculated for each of the patients in
the HDMIT group. Patients were then divided in groups with a
reduction of more or less than 50% in their CSMS (Fig 6
[upper part]) or in groups with a reduction of more or less
than 50% in their VAS score (Fig 6 [lower part]). We found
that among patients with either a CSMS (n 5 16) or a VAS
score reduction less than 50% (n 5 14) the frequencies of
IgE binding to Der p 5, Der p 7, Der p 21, and Der p 23
were higher than in patients with a CSMS (n 5 5) or VAS score
reduction greater than 50% (n 5 10), although no statistically
FIG 4. Development of IgG4 responses to allergen-derived peptides in sera from patients in the HDMIT
group during AIT. IgG4 levels (y axes show OD levels) to Der p 1–, Der p 2–, and Der p 23–derived peptides
(see Table E1) are displayed for different visits (x axes show values at V0 [baseline], V3 [33 weeks], and V4 [1
year]). Peptides that, on immunization of animals, have induced IgG antibodies blocking patients’ IgE bind-
ing to an extent greater than 40%, as indicated in Table E1, are printed in red. Horizontal red bars indicate
median values. Statistically significant differences are indicated as follows: *P < .05; **P < .01; ***P < .001;
****P < .0001.
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with IgE reactivity to Der p 5 or Der p 21 had a CSMS reduc-
tion greater than 50%. Likewise, no VAS score reduction greater
than 50% was found for patients with sensitization to Der p 5 or
Der p 21 (Fig 6). Similarly, there was no relevant VAS score
reduction for the 2 patients (ie, patients 008 and 024) who
were negative for Der p 1 and Der p 2, and no relevant reduction
in CSMS was found for 1 of the patients with available data (ie,
patient 024) (see Table E2).Patients who were sensitized exclusively to Der p 1 and/or Der
p 2 (Fig E6, A in this article’s Online Repository at www.
jacionline.org) but not to any of the other important HDM aller-
gens (ie, Der p 5, Der p 7, Der p 21, andDer p 23) showed a greater
reduction in symptoms after 1 year of treatment (a median VAS
score reduction of 59.33% [n5 10] and median CSMS reduction
of 38.24% [n59 ]) than did patients with additional sensitizations
to Der p 5, Der p 7, Der p 21, and/or Der p 23 (a median VAS score
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V0 3.65 13.36 1.96 1.66 3.31 10.46
V4 51.07 122.22 2.22 1.87 4.33 65.18
B
A
FIG 5. Effects of treatment-induced IgG antibodies on allergen-induced basophil activation. Basophils were
loaded with baseline serum IgE from patient 014 (A) and patient 029 (B) and then exposed to increasing
concentrations of HDM allergen molecules (x axes show concentrations of 0.1 ng/mL, 1 ng/mL, and
10 ng/mL) that had been preincubated with serum obtained before AIT (V0 [black bars]) or after 1 year of
AIT (V4 [gray bars]). Percentages of total b-hexosaminidase release are shown on the y axes (means 6
SDs). Allergen-specific IgG levels measured at V0 and V4 are shown for each of the patients. ISU-G, ISAC
standardized quality unit for IgG antibodies.
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FIG 6. Percentages of patients with IgE reactivity (y axes) to the clinically relevant HDM allergen molecules
(Der f 1, Der f 2, Der p 1, Der p 2, Der p 5, Der p 7, Der p 21, and Der p 23) (x axes) in the group withmore (gray
bars) or less (black bars) than a 50% reduction in CSMS and VAS scores between V0 (baseline) and V4 (1
year). The percentages of reduction were calculated as
ð100 3 ðV4 2 V0Þ
V0 and are shown for each patient in
Table E2. Numbers of patients analyzed are indicated in the figure. Two patients without IgE sensitization
to allergen molecules (patients 008 and 024) were not included.
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also not significant. The VAS score and CSMS alterations of pa-
tients from the HDMA group who had not received AIT were
different from the those of patients in the HDMIT group, with
no advantage for patients sensitized only to Der p 1 and/or Der
p 2 (see Table E3).DISCUSSION
This is the first real-life study indicating that it may be possible
to enhance the outcome HDM AIT by using a personalized
approach based on the selection of patients according to their
molecular sensitization profiles and by molecular monitoring of
the development of AIT-induced allergen-specific IgG responses.
We found that AITwith Alutard-SQ 510 induced allergen-specific
IgG responses mainly against Der p 1 and Der p 2 and, to lower
extent, to Der p 23 whereas no IgG responses to the other 3
important HDM allergens, Der p 5, Der p 7, and Der p 21, were
detectable even after 1 year of treatment. The manufacturer of
Alutard-SQ 510 does not provide information regarding the
contents of the individual HDM allergens in the vaccine. How-
ever, Casset et al have shown that HDM SPT extracts from the
company that produced Alutard-SQ 510 contained Der p 1 and/or
Der p 2 and little Der p 7 but lacked Der p 5 and Der p 21.15
Similar findings were made for natural HDM extracts produced
by other companies,15 and the analysis of an HDM AIT study
also showed that there was no induction of IgG antibodies againstDer p 5, Der p 7, and Der p 21.28 It is thus conceivable that natural
HDM allergen extracts contain much less Der p 5, Der p 7, Der p
21, and Der p 23 than Der p 1 and Der p 2.
The SCIT-induced allergen-specific IgG response consisted of
a specific IgG1 and IgG2 response that was maintained during
treatment and a continuously rising IgG4 response similar to
that observed for pollen AIT and AITwith the recombinant grass
pollen allergy vaccine BM32.46 Support for a beneficial role of the
SCIT-induced IgG response comes from our finding that the spe-
cific IgG that developed during SCIT reduced allergen-specific
basophil activation. Because our results were obtained with baso-
phils, which do not express inhibitory Fcg receptors, the mecha-
nism behind the reduction of allergen-specific basophil activation
is most likely competition of IgG with IgE for allergen binding.
Furthermore, suppression of allergen-induced basophil activation
was associated with a reduction of allergen-specific IgE binding
during testing with low amounts of microarrayed allergens, an
in vitro assay that has been described to visualize the competition
of blocking IgG antibodies with specific IgE.47,48 According to
recent studies, it is also possible that SCIT-induced IgG anti-
bodies may reduce effector cell activation by crosslinking the
allergen/IgE/IgE receptor complex with the IgG-inhibitory recep-
tor FcgRIIb,49-51 although this mechanism was found to not be of
relevance for Alutard-based AIT vaccines.52
Previous studies have shown that adult patients with allergy do
not develop new IgE sensitizations to respiratory allergens in the
natural course of disease.13,53 Interestingly, we found that SCIT
J ALLERGY CLIN IMMUNOL
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allergen-specific IgE in patients who were not sensitized against
these allergens. We found that these de novo–induced
allergen-specific IgE antibodies could lead to specific basophil
activation when loaded onto basophils, but we have no evidence
that they may be harmful considering that at the same time
much higher levels of allergen-specific IgG antibodies appeared
in the blood.
However, the most important finding from our real-life study
was that SCIT with Alutard-SQ 510 induced only a partially
protective IgG antibody response. SCIT-induced IgG responses
were directed mainly against Der p 1 and Der p 2, and to a lesser
extent to Der p 23, but not to the other 3 important HDM
allergens, Der p 5, Der p 7, and Der p 21. Der p 5, Der p 7, Der p
21, and Der p 23, but not Der p 4, must be considered clinically
relevant allergens for our patients because they induced strong
basophil degranulation even when specific IgE levels were low. In
this context, it should be noted that several other factors besides
specific IgE levels such as structural allergen determinants (eg,
number and proximity of IgE epitopes), as well as avidities of IgE
antibodies, are important for the allergenic activity of an
allergen.54,55 We even noted that not all of the Der p 1– and Der
p 2–specific IgG antibodies induced by SCIT were directed
against the major IgE binding sites of the allergens. Similar find-
ings were recently made for patients who had received SCITwith
a grass pollen allergy vaccine and a new recombinant grass pollen
vaccine, BM32, which is based on carrier-bound peptides derived
from the major IgE binding sites of the allergens.56,57 The com-
parison of IgG responses obtained by using the extract-based vac-
cine with the responses induced by BM32 showed that BM32
focused IgG responses against the IgE binding sites whereas the
allergen extract–based vaccine also induced IgG against less rele-
vant epitopes.57
Alutard-SQ 510 induced protective IgG mainly to Der p 1 and/
or Der p 2 and, to some extent, to Der p 23. The comparison of
clinical outcomes according to CSMS and VAS score assessment
indeed indicated that patients who are sensitized only to Der p 1
and/or Der p 2 benefited more from this treatment than patients
who were also sensitized to other clinically relevant HDM
allergens such as Der p 5, Der p 7, Der p 21, and Der p 23, which
are not cross-reactive with Der p 1 and/or Der p 2.58 Der p 4 was
not considered a clinically relevant allergen because it did not
induce relevant basophil degranulation in our patients. Other ex-
planations for the differences in clinical outcomes are unlikely.
First of all, the assessment of CSMS and VAS score was per-
formed outside pollen seasons, and our patients did not have rele-
vant sensitizations against other indoor allergens that played a
role. Another possibility is that patients benefiting less from
AIT had higher IgE levels against Der p 1 and/or Der p 2 and
the therapy-induced IgG could block IgE binding in these patients
less. However, this is not the case because after AIT basophil
sensitivity decreased in all Der p 1– and Der p 2–sensitized pa-
tients approximately 10-fold regardless of Der p 1– and/or Der
p 2–specific IgE levels. We therefore attribute the lower success
rate of AIT in the patients sensitized to Der p 1 and/or Der p 2
and additional allergens to the lack of induction of protective
IgG antibodies against the additional allergens.
It is a limitation of our study that only a limited number of
patients could be studied. Nevertheless, the results obtained in this
real-life study and those from an earlier HDM immunotherapy
study28 would suggest that one could increase the clinicalimprovement in HDM-specific SCIT by using a personalized
medicine approach that is either based on the stratification of pa-
tients with HDM allergy by molecular allergy diagnosis in pa-
tients who are mainly sensitized to Der p 1 and/or Der p 2 and/
or by monitoring of SCIT by molecular measurement of IgG re-
sponses. It might therefore be possible to improve the success
rate of HDMAITwith Alutard-SQ 510 by selecting for treatment
those patients who show IgE reactivity mainly to Der p 1 and/or
Der p 2 but not to Der p 5, Der p 7, and/or Der p 21. In addition,
onemay consider continuing treatment with other AIT vaccines if
it turns out that the AIT vaccine that had been selected as the first
option did not induce IgG antibodies against all the relevant aller-
gens needed. Our results may be extendable to other populations
with HDM allergy because they show IgE reactivity profiles that
are similar to those of the patients in our study.59-61 Furthermore,
our results may also be applicable to other AIT vaccines because
similar results were obtained for patients in a study of HDM
AIT.28 Of course, larger clinical studies with more patients with
HDM allergy will be needed to confirm our initial results, but
our study provides the first real-life evidence for such a personal-
ized concept for HDM-specific AIT practice.
Clinical implications:Molecular diagnosis andmolecularmoni-
toring may improve the success of HDM-specific AIT in real life
through a personalized approach.REFERENCES
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